Abstract
News on: Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress, by Wallington-Beddoe et al. Oncotarget. 2017; doi: 10.18632/oncotarget.17115.
| Original language | English |
|---|---|
| Article number | 17420 |
| Pages (from-to) | 43596-43597 |
| Number of pages | 2 |
| Journal | Oncotarget |
| Volume | 8 |
| Issue number | 24 |
| DOIs | |
| Publication status | Published - 25 Apr 2017 |
Keywords
- Sphingosine kinase 2
- multiple myeloma
- MM
- chemotherapeutic agents
- bortezomib
Cite this
Pyne, N. J., & Pyne, S. (2017). Sphingosine kinase 2 and multiple myeloma. Oncotarget, 8(24), 43596-43597. [17420]. https://doi.org/10.18632/oncotarget.17420